Drug profile · INN
fingolimod
AKM FINGOLIMOD
fingolimod (AKM FINGOLIMOD) is a sphingosine 1-phosphate receptor binding agent. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — fingolimod
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 2
- Programs
- 18
- Data quality
- 0.84
Quick answer
fingolimod (AKM FINGOLIMOD) is a sphingosine 1-phosphate receptor binding agent. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sphingosine 1-phosphate receptor binding agent
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is fingolimod?
fingolimod (AKM FINGOLIMOD) is a sphingosine 1-phosphate receptor binding agent. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for fingolimod?
AKM FINGOLIMOD is a marketed brand name for fingolimod. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fingolimod?
fingolimod has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.